IL143233A0 - Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors - Google Patents

Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors

Info

Publication number
IL143233A0
IL143233A0 IL14323399A IL14323399A IL143233A0 IL 143233 A0 IL143233 A0 IL 143233A0 IL 14323399 A IL14323399 A IL 14323399A IL 14323399 A IL14323399 A IL 14323399A IL 143233 A0 IL143233 A0 IL 143233A0
Authority
IL
Israel
Prior art keywords
receptors
increase
receptor
diseases associated
treating diseases
Prior art date
Application number
IL14323399A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26152118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL143233(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP98811258A external-priority patent/EP1013273A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL143233A0 publication Critical patent/IL143233A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL14323399A 1998-12-23 1999-12-22 Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors IL143233A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98811258A EP1013273A1 (en) 1998-12-23 1998-12-23 Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
EP98811257 1998-12-23
PCT/EP1999/010330 WO2000038676A1 (en) 1998-12-23 1999-12-22 Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors

Publications (1)

Publication Number Publication Date
IL143233A0 true IL143233A0 (en) 2002-04-21

Family

ID=26152118

Family Applications (5)

Application Number Title Priority Date Filing Date
IL14323399A IL143233A0 (en) 1998-12-23 1999-12-22 Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
IL143233A IL143233A (en) 1998-12-23 2001-05-17 The use of Wolsartan or its common pharmaceutical salt for the preparation of a medicinal preparation for the treatment of lung cancer and invasive breast cancer
IL179016A IL179016A0 (en) 1998-12-23 2006-11-02 Compressed tablet comprising valsarta
IL179015A IL179015A0 (en) 1998-12-23 2006-11-02 Compressed tablet comprising valsartan
IL179017A IL179017A0 (en) 1998-12-23 2006-11-02 Solid oral dosage form comprising valsartan

Family Applications After (4)

Application Number Title Priority Date Filing Date
IL143233A IL143233A (en) 1998-12-23 2001-05-17 The use of Wolsartan or its common pharmaceutical salt for the preparation of a medicinal preparation for the treatment of lung cancer and invasive breast cancer
IL179016A IL179016A0 (en) 1998-12-23 2006-11-02 Compressed tablet comprising valsarta
IL179015A IL179015A0 (en) 1998-12-23 2006-11-02 Compressed tablet comprising valsartan
IL179017A IL179017A0 (en) 1998-12-23 2006-11-02 Solid oral dosage form comprising valsartan

Country Status (26)

Country Link
EP (3) EP1588706B1 (ko)
JP (2) JP2002533390A (ko)
KR (1) KR100646716B1 (ko)
CN (2) CN1304000C (ko)
AT (2) ATE524176T1 (ko)
AU (4) AU3043000A (ko)
BR (1) BR9916576A (ko)
CA (2) CA2351357A1 (ko)
CY (2) CY1106581T1 (ko)
CZ (2) CZ293257B6 (ko)
DE (1) DE69935249T2 (ko)
DK (2) DK1588706T3 (ko)
ES (2) ES2373556T3 (ko)
HK (1) HK1038888B (ko)
HU (1) HUP0104780A3 (ko)
ID (1) ID29856A (ko)
IL (5) IL143233A0 (ko)
NO (2) NO328775B1 (ko)
NZ (3) NZ587909A (ko)
PL (1) PL199100B1 (ko)
PT (2) PT1588706E (ko)
RU (3) RU2271809C2 (ko)
SI (2) SI1140071T1 (ko)
SK (1) SK9132001A3 (ko)
TR (7) TR200605471T2 (ko)
WO (1) WO2000038676A1 (ko)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ540748A (en) * 2000-06-22 2007-04-27 Novartis Ag An oral solid pharmaceutical composition comprising valsartan and a filler in a weight ratio from 2:1 to 1:1
JP4972847B2 (ja) * 2000-10-11 2012-07-11 住友化学株式会社 コラーゲン蓄積抑制剤
WO2002083127A1 (fr) * 2001-04-09 2002-10-24 Tokai University Educational System Compositions inhibant la modification proteique
DE60222409T2 (de) 2001-05-31 2008-09-25 Vicore Pharma Ab Trizyklische verbindungen, nützlich als angiotensin ii agonisten
WO2003041739A1 (en) 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Anticaner agents
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
SK50472005A3 (sk) * 2003-11-03 2005-09-08 Zentiva, A. S. Tableta s obsahom valsartanu vyrobená priamym tabletovaním
US20080102120A1 (en) 2004-12-24 2008-05-01 Miha Vrbinc Solid Pharmaceutical Composition Comprising Valsartan
ES2425567T3 (es) * 2004-12-24 2013-10-16 Spinifex Pharmaceuticals Pty Ltd Método de tratamiento o profilaxis
WO2006136916A2 (en) * 2005-06-20 2006-12-28 Glenmark Pharmaceuticals Limited Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same
GT200600371A (es) 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
ES2246742B1 (es) * 2005-09-06 2007-02-01 Prous Institute For Biomedical Research S.A. Uso de un derivado de imidazol.
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
CA2681708A1 (en) * 2007-03-29 2008-10-09 Alembic Limited Valsartan tablet formulations
TR200703568A1 (tr) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
US20100222334A1 (en) 2007-10-09 2010-09-02 Wayne Talamonti Pharmaceutical Formulation of Valsartan
SI3067043T1 (sl) 2007-11-06 2023-04-28 Novartis Ag Farmacevtski sestavki na osnovi superstruktur antagonista/blokatorja angiotenzinskega receptorja (ARB) in zaviralca nevtralne endopeptidaze (NEP)
WO2009092052A2 (en) * 2008-01-18 2009-07-23 Massachusetts Eye And Ear Infirmary Methods and compositions for treating polyps
GB0802931D0 (en) * 2008-02-18 2008-03-26 Queen Mary & Westfield College Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions
EP2405899A2 (en) 2009-03-11 2012-01-18 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Valsartan formulations
EP2536396B1 (en) 2010-02-16 2016-08-10 KRKA, D.D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
EP2455388A1 (en) 2010-11-23 2012-05-23 LanthioPep B.V. Novel angiotensin type 2 (AT2) receptor agonists and uses thereof.
CN102266307B (zh) * 2011-08-01 2012-10-24 海南锦瑞制药股份有限公司 一种缬沙坦胶囊及其制备方法
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
EA018867B1 (ru) * 2012-11-01 2013-11-29 Лаборатория Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции и продукт способа
EP4007592A1 (en) 2019-08-02 2022-06-08 LanthioPep B.V. Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide
WO2024026528A1 (en) * 2022-08-02 2024-02-08 Dimerix Bioscience Pty Ltd Dosage regimen for the treatment of copd

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3146168A (en) * 1962-04-10 1964-08-25 Fmc Corp Manufacture of pharmaceutical preparations containing cellulose crystallite aggregates
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
ATE108996T1 (de) * 1988-02-25 1994-08-15 Brocades Pharma Bv Verfahren zur herstellung eines pharmazeutischen granulats.
ATE190051T1 (de) 1989-06-14 2000-03-15 Smithkline Beecham Corp Imidazoalkensäure
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
EP0443983B1 (de) 1990-02-19 1996-02-28 Ciba-Geigy Ag Acylverbindungen
PT97078B (pt) 1990-03-20 1997-07-31 Sanofi Sa Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IE912956A1 (en) 1990-09-10 1992-03-11 Abbott Lab Angiotensin ii receptor antagonists
JP3208139B2 (ja) 1990-10-02 2001-09-10 ワーナー−ランバート・コンパニー アンギオテンシン▲ｉｉ▼アンタゴニスト
DE4038335A1 (de) * 1990-12-01 1992-06-04 Boehringer Mannheim Gmbh Neue pyridinderivate, verfahren zu ihrer herstellung und verwendung als arzneimittel
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5591762A (en) * 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
US5196537A (en) 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9110636D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
DE4132632A1 (de) * 1991-10-01 1993-04-08 Bayer Ag Substituierte imidazolyl-propensaeurederivate
DE4309968A1 (de) * 1993-03-26 1994-09-29 Bayer Ag Phenylglycinamide von heterocyclisch substituierten Phenylessigsäurederivaten
DE69325574T2 (de) 1992-04-13 2000-03-16 Zeneca Ltd ANGIOTENSIN-II-ANTAGONISTEN GEGEN ERKRANKUNGEN; DIE MIT EINER EINGESCHRäNKTEN; NEURONALEN LEITUNGSGESCHWINDIGKEIT VERBUNDEN SIND, INSBESONDERE DIABETISCHE NEUROPATHIE
US5683997A (en) * 1992-12-11 1997-11-04 Ciba-Geigy Corporation Substituted benzazepinones
US5610153A (en) 1992-12-11 1997-03-11 Ciba-Geigy Corporation Benzazepinone derivatives
DE4309963A1 (de) * 1993-03-26 1994-09-29 Hubert Kamperschroer Faß zum Austragen von Gülle
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
DE4408497A1 (de) 1994-03-14 1995-09-21 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
HUT76542A (en) 1994-03-17 1997-09-29 Ciba Geigy Ag Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy
DE4432860A1 (de) * 1994-09-15 1996-03-21 Merck Patent Gmbh Imidazopyridine
DK0853477T3 (da) 1995-10-06 2003-02-10 Novartis Ag AT1-receptor-antagonister til forebyggelse og behandling af postiskæmisk nyresvigt og til beskyttelse af iskæmiske nyrer
WO1997031624A1 (en) 1996-02-27 1997-09-04 Purdue Research Foundation Liposomal delivery system
ES2189940T3 (es) 1996-02-29 2003-07-16 Novartis Ag Antagonista de receptor at1 para la estimulacion de la apoptosis.
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
DE19628617A1 (de) * 1996-07-16 1998-01-22 Basf Ag Direkttablettierhilfsmittel
CZ299429B6 (cs) * 1998-07-10 2008-07-23 Novartis Ag Lék obsahující kombinaci valsartanu a blokátoru kalciového kanálu
DE60028928T2 (de) 1999-01-26 2007-01-04 Novartis Ag Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
NZ540748A (en) * 2000-06-22 2007-04-27 Novartis Ag An oral solid pharmaceutical composition comprising valsartan and a filler in a weight ratio from 2:1 to 1:1
US20070123498A1 (en) 2003-10-17 2007-05-31 Shetty Suraj S Combination of organic compounds
JP2009018990A (ja) 2005-10-25 2009-01-29 Univ Kurume Ｃ型肝炎ウイルス由来ペプチド

Also Published As

Publication number Publication date
EP1588706B1 (en) 2011-09-14
SI1588706T1 (sl) 2012-01-31
TR200605472T1 (tr) 2007-02-21
HUP0104780A3 (en) 2002-11-28
TR200805740T1 (tr) 2010-06-21
EP1588706A3 (en) 2005-12-07
NZ587909A (en) 2012-05-25
JP5254258B2 (ja) 2013-08-07
RU2361575C2 (ru) 2009-07-20
TR200805275T2 (tr) 2008-09-22
PT1588706E (pt) 2011-12-21
AU2009220022B2 (en) 2011-11-03
CY1106581T1 (el) 2012-01-25
EP1140071A1 (en) 2001-10-10
RU2271809C2 (ru) 2006-03-20
CZ20012306A3 (cs) 2001-12-12
AU3043000A (en) 2000-07-31
CZ293257B6 (cs) 2004-03-17
NZ553010A (en) 2008-09-26
NO328775B1 (no) 2010-05-10
TR200805741T2 (tr) 2008-10-21
CN1636561A (zh) 2005-07-13
AU2003266433B2 (en) 2006-08-10
PL349424A1 (en) 2002-07-29
IL179016A0 (en) 2007-03-08
KR100646716B1 (ko) 2006-11-17
NO20013143D0 (no) 2001-06-22
SI1140071T1 (sl) 2007-08-31
CN1304000C (zh) 2007-03-14
ES2373556T3 (es) 2012-02-06
DK1588706T3 (da) 2012-01-16
CY1112395T1 (el) 2015-12-09
DE69935249T2 (de) 2007-10-31
HK1038888A1 (en) 2002-04-04
JP2010090169A (ja) 2010-04-22
TR200101784T2 (tr) 2001-10-22
HK1038888B (zh) 2007-09-21
CN1331590A (zh) 2002-01-16
RU2005124363A (ru) 2007-02-10
JP2002533390A (ja) 2002-10-08
RU2008143545A (ru) 2010-05-10
EP2298298A2 (en) 2011-03-23
KR20010089681A (ko) 2001-10-08
DE69935249D1 (de) 2007-04-05
AU2003266433A1 (en) 2004-01-08
WO2000038676A1 (en) 2000-07-06
PL199100B1 (pl) 2008-08-29
ATE524176T1 (de) 2011-09-15
NO20100041L (no) 2001-08-16
TR200200764T2 (tr) 2002-07-22
HUP0104780A2 (hu) 2002-04-29
NO20013143L (no) 2001-08-16
IL179017A0 (en) 2007-03-08
BR9916576A (pt) 2001-10-02
ATE354364T1 (de) 2007-03-15
TR200605471T2 (tr) 2006-11-21
ES2281978T3 (es) 2007-10-01
NZ511938A (en) 2004-02-27
CA2351357A1 (en) 2000-07-06
DK1140071T3 (da) 2007-06-04
SK9132001A3 (en) 2002-01-07
PT1140071E (pt) 2007-05-31
ID29856A (id) 2001-10-18
AU2009220022A1 (en) 2009-10-15
CA2622805A1 (en) 2000-07-06
EP2298298A3 (en) 2011-05-11
CA2622805C (en) 2011-05-10
EP1588706A2 (en) 2005-10-26
AU2006203077B2 (en) 2009-10-08
CZ297795B6 (cs) 2007-03-28
IL179015A0 (en) 2007-03-08
IL143233A (en) 2007-07-24
EP1140071B1 (en) 2007-02-21
AU2006203077A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
HK1038888A1 (en) Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
IL146871A0 (en) Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
IL127244A0 (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
WO1999026927A3 (en) Metabotropic glutamate receptor antagonists for treating central nervous system diseases
HUP0102300A3 (en) Use of diazepin derivatives for preparing medicines for treating diseases influenced by somatostatine receptor, and new compounds
AU2002360436A1 (en) 2-aryl pyrrologpyrimidines for a1 and a3 receptors
EP1149078A4 (en) 5-HT 6 RECEPTOR LIGANDS? SELECTIVE
IL147977A0 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
WO2000012623A3 (en) Use of 5-th receptor antagonists for the treatment of parkinson's disease
BG104038A (en) Use of specific antagonist of 5ht2 receptors for preparing medicines useful for treating sleep-disordered breathing
NZ332829A (en) Use of a polypeptide corresponding to a serine threonine kinase receptor, ALK-7 for neurological diseases
CA2311423A1 (en) Method for treating hyperlipidemia
HU9801792D0 (en) 4-aminopyrrole(3,2-d)pyrimidines as neuropeptide y receptor antagonists
SI1200402T1 (sl) Substituirani 1,5-dihidropirol-2-on-derivati, ucinkoviti kot antagonisti NMDA-receptorja za tretiranje bolecinskih stanj
SI1148881T1 (sl) Uporaba derivatov pridazino - (4,5-(b))-indol-1-acetamida za pripravo zdravil za bolezni, povezane z disfunkcijo perifernih benzodiazepinskih receptorjev
WO2002007726A8 (en) Treatment of movement disorders

Legal Events

Date Code Title Description
ERR Corrigendum

Free format text: IN JOURNAL 5/2007 P. 1958 PATENT APPLICATION NO. 143233 DELETE THE APPLICATION. THE APPLICATION WASPUBLISHED BY MISTAKE. THE APPLICATION HAS NOT YET BEEN ACCEPTED AND IS NOT OPEN TO THE PUBLIC

FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees